A key problem is the ability of glioma stem cells to regenerate tumors after treatment and resist conventional therapies, making them a primary reason for treatment failure. Recent discoveries ...

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral ...

Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel formation. Stem cell-like glioma ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

Glioblastoma multiforme (GBM), commonly referred to as glioblastoma, is a malignant intracranial tumor derived from glial ...

High- grade gliomas remain one of the most challenging ... CIRM has provided billions in funding to support stem cell, genetic research, and development programs in its portfolio.

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...